ArticleMarine drugs2020
Oral Fucoidan Attenuates Lung Pathology and Clinical Signs in a Severe Influenza a Mouse Model.
Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Algae extract supplementation boosts humoral immunity induced by attenuated PRRSV-1 vaccination.BMC veterinary research · 2025Article
- Beyond Nutrition: The Therapeutic Promise of Seaweed-Derived Polysaccharides Against Bacterial and Viral Threats.Marine drugs · 2025Review
- Fucoidan-based Nanomedicine for Hearing Loss: Emerging Roles as Carrier and Therapeutic Agent.Pharmaceutical research · 2025Review
- Antiviral activity of natural and modified hydrocolloids: main sources, susceptible viruses, structure-activity relationship and mechanisms of action.Frontiers in nutrition · 2025Review
- Exploring the effect and mechanism of fucoidan on liver cancer depending on network pharmacology and experimental verification.Frontiers in chemistry · 2025Article
- A state-of-the-art review on fucoidan as an antiviral agent to combat viral infections.Carbohydrate polymers · 2022Review
- Therapeutic activity of fucoidan and carrageenan as marine algal polysaccharides against viruses.3 Biotech · 2022Review
- Antiviral Activity and Mechanisms of Seaweeds Bioactive Compounds on Enveloped Viruses-A Review.Marine drugs · 2022Review
- Therapeutic Applications of Fucoidans and their Potential to Act Against COVID-19.Current pharmaceutical design · 2022Review
- Fucoidan Protects against Acute Sulfoxaflor-Induced Hematological/Biochemical Alterations and Oxidative Stress in Male Mice.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Review
- Pharmacological Activities of Sulfated Fucose-Rich Polysaccharides after Oral Administration: Perspectives for the Development of New Carbohydrate-Based Drugs.Marine drugs · 2021Review
- Marine Sulfated Polysaccharides as Promising Antiviral Agents: A Comprehensive Report and Modeling Study Focusing on SARS CoV-2.Marine drugs · 2021Article
- Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: A review of antiviral potential throughout pathogenesis.Algal research · 2021Article
- On the Health Benefits vs. Risks of Seaweeds and Their Constituents: The Curious Case of the Polymer Paradigm.Marine drugs · 2021Article
- Antiviral Potential of Algal Metabolites-A Comprehensive Review.Marine drugs · 2021Review
- Fucoidan and Lung Function: Value in Viral Infection.Marine drugs · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucoidans are known to be effective inhibitors of inflammation, and of virus binding and cellular entry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.